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Abstract: Dental pulp stem cells (DPSCs) from adult teeth show the expression of a very complete
repertoire of stem pluripotency core factors and a high plasticity for cell reprogramming. Canonical
Wnt and Notch signaling pathways regulate stemness and the expression of pluripotency core factors in
DPSCs, and even very short-term (48 h) activations of the Wnt pathway induce a profound remodeling
of DPSCs at the physiologic and metabolic levels. In this work, DPSC cultures were exposed to
treatments modulating Notch and Wnt signaling, and also induced to differentiate to osteo/adipocytes.
DNA methylation, histone acetylation, histone methylation, and core factor expression levels where
assessed by mass spectroscopy, Western blot, and qPCR. A short-term activation of Wnt signaling
by WNT-3A induced a genomic DNA demethylation, and increased histone acetylation and histone
methylation in DPSCs. The efficiency of cell reprogramming methods relies on the ability to surpass the
epigenetic barrier, which determines cell lineage specificity. This study brings important information
about the regulation of the epigenetic barrier by Wnt signaling in DPSCs, which could contribute to the
development of safer and less aggressive reprogramming methodologies with a view to cell therapy.
Keywords: dental pulp stem cells; chromatin remodeling; cell cycle; pluripotency; DNA methylation;
histone acetylation; histone methylation; Notch pathway; Wnt pathway
1. Introduction
Dental pulp stem cells or DPSCs arise from the neural crest (NC) as many other cells of
craniomaxillofacial tissues [1–7]. Interestingly, DPSCs present some advantages with respect to other
multipotent stem cell populations found in the adult human body [8–10], and they show a relatively high
expression of core pluripotency factors like OCT4, SOX2, KLF4, LIN28, SSEA1, and NANOG [2,9–13].
The expression of those core factors regulates stem cell pluripotency [14–18]. The use of DPSCs could
also be very relevant to cell therapy because these cells are also known to be easily accessible for
extraction under aseptic conditions, well-tolerated upon grafting due to their immune-suppressive
properties [19], non-tumorigenicity [20], and suitability for autologous therapy [7,21,22].
Classical experiments showed that somatic cells could be reprogrammed into a pluripotent state
by the ectopic expression of just a few core factors. The first recipe ever published featured the
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so-called Yamanaka factors: OCT4, SOX2, KLF4, and C-MYC [23]. Later on, other combinations of core
factors with reprogramming effect were characterized, like: OCT4, SOX2, NANOG, and LIN28A [16].
However, the efficiency of these and other related reprogramming methods is usually very low (<1%),
because of the restrictions imposed by the epigenetic determination barrier, which carries with it all the
history of the starting parental adult cell [23,24]. Cell reprogramming and the induction of pluripotency
depend critically on the erasure of the epigenetic tags linked to cell differentiation. Therefore, the study
of these multiple epigenetic modifications associated with the differentiation process, and how these
could be reversed, is of paramount importance. Some authors have demonstrated the superior ability
of DPSCs to undergo full cell reprogramming. This was associated to a relatively non-methylated
state of the DPSC genome in some critical loci, showing a fairly similar methylation pattern to that
found in pluripotent stem cells (PSCs) such as embryonic stem cells (ESCs) and induced pluripotent
stem cells (iPSCs) [25]. Recent studies also showed that inhibition of DNA methylation enhanced the
reprogramming efficiency of gingival mesenchymal stem cells (hGMSCs; a population derived from
neural crest as DPSCs), into embryoid body forming PSCs, suggesting the possible application of these
approaches in autologous cell therapy and organ repair [26].
The epigenome of stem cells is different from the genome of differentiated cells. Stem cells
present a genome predominantly in euchromatic conformation whereas the genome of somatic cells is
more enriched in heterochromatin, with a higher amount of genes permanently silenced by cytosine
methylation [27–29]. It is also known that DNA methylation levels are low in PSCs both in vitro and
in vivo [24,30]. Additionally, a high level of histone acetylation in PSCs is known to contribute to
the weakening of the interaction with DNA, leading to the unfolding of chromatin and activation of
gene transcription [31]. Contrarily, the loss of acetylation catalyzed by histone deacetylases (HDACs)
leads to a closed heterochromatin conformation, thereby repressing transcriptional activity [32].
Chromatin remodeling in PSCs is also regulated by histone methylation. The most characterized are
the tri-methylation marks of Histone 3, and the general description attributes to H3K4me3 a role as a
gene activator mark, whereas H3K9me3 and H3K27me3 are known as repressive marks associated
with transcriptional silencing [33]. In fact, a distinctive characteristic of PSCs is the presence of bivalent
domains containing both activating (H3K4me3) and repressing (H3K27me3) histone methylation
marks in genes governing cell stemness and differentiation [34–37]. These bivalent domain-containing
genes would enable the stem cell to respond to changes in the environment by rapidly activating the
transcription of specific sets of genes while repressing others [35,38].
The canonical Notch and Wnt signaling pathways are widely regarded as important regulators of
stemness [39–43] and cell differentiation [44–46] in DPSCs and many other stem cell types. It is known
that dental stem cells present particularly high levels of Wnt and Notch pathway activity, which relates to
their high expression of pluripotency core factors and high ability for cell reprogramming [2,9,13,47,48].
However, the epigenetic regulations that these pathways may exert on DPSCs are still unclear. A better
understanding of how Notch and Wnt influence the epigenetic tags in DPSCs could lead to significant
improvements in the efficiency of the current nuclear reprogramming methodologies using these
cells, and in the ex vivo expansion of stem and differentiated cells for cell transplant therapies. For
this purpose, we studied the epigenetic profile of DPSCs treated with Notch and Wnt signaling
pharmacological modulators and we assessed the similarities and differences in the DNA methylation,
histone methylation and histone acetylation patterns comparing to control DPSCs, DPSCs exposed to
osteogenic and adipogenic differentiation conditions, and PSCs.
2. Materials and Methods
2.1. DPSC Culture
DPSCs were isolated from human third molars obtained from healthy donors between 18 and
30 years of age, who gave their informed consent for donation, following the approval of the CEISH
committee of UPV/EHU for research with human samples, and abiding by the ethical principles of
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the Declaration of Helsinki on medical research involving human subjects. Teeth were fractured and
enzymatic digestion of the pulp tissue was carried out for 1 h at 37 ◦C with 3 mg/mL collagenase
(17018-029, Thermo Fisher Scientific, Waltham, MA, USA) and 4 mg/mL dispase (17105-041, Thermo
Fisher Scientific), followed by mechanical dissociation. The DPSCs were cultured in Dulbecco’s
modified Eagle’s medium (DMEM) supplemented with 10% fetal bovine serum (FBS), L-glutamine
(1 mM) and the antibiotics penicillin (100 U/mL) and streptomycin (150 µg/mL). After 1 week in culture,
practically 100% of cells were positive for the neural markers Nestin, β3-tubulin, the mesenchymal
markers Collagen I, CD90, CD105, CD73, and negative for the haematopoietic marker CD45 [49].
The DPSCs could be amplified and maintained in these conditions for very long periods (>6 months).
However, to avoid cell aging issues, we only employed DPSCs that had been grown in culture for
less than 3 months and had accumulated no more than 6 total passages. Comparative experiments
between control and treatment conditions were always and without exception performed in parallel
using DPSCs from the same donor.
2.2. ESC Culture
Mouse Oct4-GFP ES Cells (PCEMM08; PrimCells LLC, San Diego, CA, USA) were cultured
in 2i+LIF feeder-free culture conditions on a dish coated with gelatin (0.01%) in Knockout DMEM
medium (Knockout serum replacement 15%, sodium pyruvate 1mM, non-essential aminoacids
supplement 1% (M7145, Sigma, San Luis, MO, USA), penicillin/streptomicin 100 U/mL, L-glutamine
1% and β-mercaptoethanol 0.007% with 2i (PD0325901, 0.4 mM; Stemgent, San Diego, CA, USA,
and CHIR99021, 3 mM; Stemgent, San Diego, CA, USA) and LIF(1000U/mL; Sigma, San Luis, MO,
USA). The expanded ESC colonies were passaged by dissociation with TrypLE (Invitrogen, Carlsbad,
CA, USA).
2.3. Notch and Wnt Pathway Pharmacological Modulation
To block Notch signaling, we employed DAPT ((N-[N (3, 5-diflorophenacetyl-L-alanyl)]
5-phnylglycine t-butyl ester), a γ-secretase inhibitor, (565784, Calbiochem, San Diego, California,
CA, USA), at a concentration of 2.5 µM. DAPT was added to the culture medium for 48 h prior to
the assays where DAPT-treated DPSCs were compared with DPSCs treated only with the control
vehicle DMSO. To activate Wnt signaling, we used 2.5 µM BIO (6-bromoindirubin-3′-oxine), a GSK3β
inhibitor (361550, Calbiochem, San Diego, CA, USA), which was added to the medium for 48 h
prior to the assays. BIO-treated cells were compared with DPSCs exposed to the inactive analog
MBIO (methyl-6-bromoindirubin-3′-oxine) at 2.5 µM as a corresponding control (361556, Calbiochem).
WNT-3A recombinant protein (5036-WN-010, R&D Systems, Minneapolis, MN, USA) was diluted
in PBS and also added at 2.5 µM for 48 h to the DPSCs cultures as another treatment to activate
Wnt signaling.
2.4. Osteogenic Differentiation of DPSCs
We used the following protocol to induce DPSC differentiation to mature osteoblasts: 6 µM
β-glycerolphosphate (G9422, Sigma-Aldrich, St. Luis, MO, USA), 10 nM dexamethasone (D4902, Sigma,
San Luis, MO, USA), and 52 nM ascorbic acid (127.0250, Merck, Darmstadt, Germany) were added to
the cell cultures in DMEM + 10% FBS for three weeks prior to the assays. Osteoblastic differentiation
pre-commitment was assessed by Alkaline Phosphatase (ALP) staining in control and treated cells.
Cells were fixed for 1min using 4% paraformaldehyde and washed with 0.05% Tween 20 in PBS.
ALP staining was performed using 5-Bromo-4-chloro-3-indolyl phosphate/Nitro Blue tetrazolium
(BCIP/NBT; Sigma, San Luis, MO, USA) as chromogen substrate, and the staining progress was checked
every 3 min. After the incubation, cells were washed three times with PBS and ALP absorbance at
405 nm was quantified using a Synergy HT Multi-Mode Microplate Reader (Biotek, Winooski, VT,
USA). Terminal differentiation to mature mineralizing osteoblast/osteocyte lineage cells was assessed
at 3 weeks post-induction by detection of extracellular calcified bone matrix deposits via Alizarin
Cells 2020, 9, 652 4 of 21
Red staining, using 2 g/100 mL Alizarin Red S (400480250, Across Organics, Geel, Belgium) at pH 4.3.
DPSCs were fixed with 10% formalin (F7503, Sigma, San Luis, MO, USA) for 30 min, incubated with the
Alizarin S Red solution for 45 min, and washed four times with PBS to remove any background staining.
Alizarin Red absorbance at 450 nm was quantified using a Synergy HT Multi-Mode Microplate Reader
(Biotek, Winooski, VT, USA).
2.5. Adipogenic Differentiation of DPSCs
To induce adipogenic differentiation, we treated DPSC cultures with 0.5 mM IBMX (I5879,
Sigma, San Luis, USA), 1 µg/mL insulin (91077C, SAFC Biosciences, St. Luis, MO, USA) and 1 µM
dexamethasone (D4902, Sigma, San Luis, MO, USA) for four weeks prior to the assays. Terminal
differentiation to adipocytes was assessed by Oil Red staining. Cells were fixed with 10% formalin for
10 min and then washed with PBS containing 60% Isopropanol. Lipid droplets in mature adipocytes
were detected by incubation with a solution containing 5.14 µM Oil Red Stock (O-0625, Sigma, San Luis,
MO, USA) in miliQ water for 10 min. Oil Red absorbance was measured at 490 nm using a Synergy HT
Multi-Mode Microplate Reader (Biotek, Winooski, VT, USA).
2.6. RNA Extraction, Reverse Transcription and Quantitative Real-Time PCR (qPCR)
Cell pellets were frozen and stored at −80 ◦C. Total RNA was extracted from the cells using the
RNeasy Kit (74104, Qiagen, Hilden, Germany) and checked for purity by measuring the 260/280 ratio
in the Nanodrop Synergy HT instrument (Biotek, Winooski, VT, USA). cDNA (50 ng/µL) was obtained
by reverse transcription of total extracted RNA using the iScript cDNA Kit (1708890, BioRad, Hercules,
CA, USA) with the following reagents: iScript reverse Transcriptase (1 µL), 5× iScript Reaction Mix
(4µL) and Nuclease Free water (variable) to a final volume of 20 µL. Quantitative Real-Time PCR
experiments were conducted in an iCycler My iQTM Single-Color Real-Time PCR Detection System
(BioRad, Hercules, CA, USA), using 4.5 µL of Power SYBR® Green PCR Master Mix 2× (4367659,
Applied BiosystemsTMApplied Biosystems, Carlsbad, CA, USA), 0.5 µL of primers (0.3125 µM), 0.3 µL
of cDNA (1.5 ng/µL) and Nuclease Free water for a total volume reaction of 10 µL. All primers were
obtained from public databases and checked for optimal efficiency (>90%) in the qPCR reaction
under our experimental conditions. The relative expression of each gene was calculated using the
standard 2-∆Ct method [50] normalized with respect to the average of β-ACTIN and GAPDH as internal
housekeeping control genes. All reactions were performed in triplicate. qPCR was run on a CFX96®
thermo cycler (BioRad, Hercules, CA, USA). Data were processed by CFX Manager™ Software (BioRad,
Hercules, CA, USA). We assessed that all qPCR reactions yielded only one amplification product by
the melting curve method. We used the following primer pairs for different human and mouse gene
transcripts obtained via Primer Bank and validated by the NCBI Primer-Blast method (Table 1).
Table 1. Primer pairs to assess gene transcript expression in DPSCs by qPCR.
Primers Sequence 5′–3′ Annealing (ºC) Amplicon (bp)
β-ACTIN
Upstream GTTGTCGACGACGAGCG 58.5
93
Downstream GCACAGAGCCTCGCCTT 59.7
GAPDH
Upstream CTTTTGCGTCGCCAG 60.3
131
Downstream TTGATGGCAACAATATCCAC 60.8
DNMT1
Upstream CGTAAAGAAGAATTATCCGAGG 60.5
123
Downstream GTTTTCTAGACGTCCATTCAC 57.7
DNMT3A
Upstream GAAGAGAAGAATCCCTACAAAG 57.6
136
Downstream CAATAATCTCCTTGACCTTGG 60
DNMT3B
Upstream CTTACCTTACCATCGACCTC 57.7
167
Downstream ATCCTGATACTCTGAACTGTC 54.7
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Table 1. Cont.
Primers Sequence 5′–3′ Annealing (ºC) Amplicon (bp)
NNMT
Upstream CTGACTACTCAGACCAGAAC 53.6
113
Downstream TCTGTTCCCTTCAAGATCAC 59.3
KAT8/HAC
Upstream GAAATATGAGAAGAGCTACCG 57.2
123
Downstream ATCTTATGGTCTTTGCCATC 58
SIRT1/HDAC
Upstream AAGGAAAACTACTTCGCAAC 57.6
89
Downstream GGAACCATGACACTGAATTATC 59.7
OCT4A
Upstream CGTGAAGCTGGAGAAGGAGA 60.7
137
Downstream CATCGGCCTGTGTATATCCC 60.1
CMYC
Upstream GTCAAGAGGCGAACACACAAC 59.8
162
Downstream TGGACGGACAGGATGTATGC 59.8
NANOG
Upstream GTCAAGAAACAGAAGACCAG 56.4
184
Downstream GCCACCTCTTAGATTTCATTC 59.2
SOX2
Upstream ATAATAACAATCATCGGCGG 61.1
90
Downstream AAAAAGAGAGAGGCAAACTG 57.8
CYCLIN D1
Upstream TGAGGCGGTAGTAGGACAGG 60.4
140
Downstream GACCTTCGTTGCCCTCTGT 59.6
EZH2
Upstream CCAACACAAGTCATCC 60.4
91
Downstream CCATAAAATTCTGCTGTAGGG 59.6
MLL
Upstream AAAGACTTCTAAGGAGGCAG 61.1
183
Downstream AACATATAGCAACCAATGCC 58.7
EHMT2
Upstream CTGTCAGAGGAGTTAGGTTC 60.4
135
Downstream ATCCACAGAGTAGGAATCATAG 59.6
PPARγ
Upstream AAAGAAGCCAACACTAAACC 57.4
78
Downstream TGGTCATTTCGTTAAAGGC 60.1
LPL
Upstream ACACAGAGGTAGATATTGGAG 54.8
143
Downstream CTTTTTCTGAGTCTCTCCTG 55.7
SPARC
Upstream CTTCAGACTGCCCGGAGA 61.1
90
Downstream GAAAGAAGATCCAGGCCCTC 60.2
OSTERIX
Upstream TGAGGAGGAAGTTCACTATG 53.8
200
Downstream CATTAGTGCTTGTAAAGGGG 54.0
2.7. Protein Extraction
DPSCs were washed with hand-warm PBS several times, and the proteins were lysed on ice with
200 µl Lysis Buffer (50 mM Tris-HCl pH 7.5, 1mM EDTA, 150 mM NaCl, 0.5% sodium deoxycholate,
0.1% SDS, 1% IGEPAL® CA-630 in dH2O), Proteinase Inhibition (1:100, 539134, Calbiochem) and
phosphatase inhibitor cocktail (1:100, 539134, Calbiochem, San Diego, CA, USA). After an incubation
of 5 min lysates were scrapped thoroughly and transferred to a pre-chilled 1.5 mL tube and submitted
to homogenization in a Bandelin Plus sonicator using a 1.5 MS probe. After three sonication bursts
on ice for 20 s at 90% amplitude with 1 min of rest in between each of them, lysates were cleared by
centrifugation at 20,000 rcf for 10 min at 4 ◦C. Supernatants were quantified using CuSO4-BCA in
50:1 ratio (B9643, Sigma, San Luis, MO, USA), BSA (A7906, Sigma, San Luis, MO, USA) was used for
performing a linear relationship with concentration and absorbance at 490nm. Samples were read in
the Nanodrop Synergy HT (Biotek, Winooski, VT, USA).
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2.8. Western Blot (WB)
The samples with 30 µg of total protein were diluted in loading buffer (62.5 mM Tris-HCl, pH 6.8,
2.5% SDS; 10% glycerol; 5% β-mercaptoethanol and 0.002% bromophenol blue). After electrophoretic
separation (electrophoresis buffer formulation: 25 mM Tris, pH 8.3; 193 mM glycine, 0.1% SDS) under
constant 120 V, proteins were blotted during 3 h (250 V max, 600 W max, constant 400 mA) using
Transfer buffer: 25 mM, Tris pH 8.3; 192 mM glycine; 20% methanol; 0.1% SDS) onto 0.2 µm-pore
nitrocellulose membranes using the Mini-PROTEAN tetra system and Mini Trans-Blot cell respectively
fed by a PowerPac HVTM High-Current Power Supply. Once correct protein transfer was confirmed
by Ponceau S protein staining, membranes were washed with TBST (10 Mm Tris-HCl, pH 8; 150 mM
NaCl; 0.05% Tween 20) until all dye was gone and submitted to blockage using 1% BSA diluted in
TBST during 1 h at room temperature under constant agitation. For Western blot analyses, we used
anti α-TUBULIN (1:3000, 4967, Cell Signaling, Massachusetts, MA, USA), anti-H3K9me3 (1:2000, 9542S,
Cell Signaling, Massachusetts, MA, USA), anti-H3K4me3 (1:1000, ab12209, Abcam, Massachusetts, MA,
USA), anti-H3K27me3 (1:1000, ab6002, Abcam, Massachusetts, MA, USA), anti-H3AC (1:2000, 06–599,
Millipore) anti-DNMT1 (1:2000, 60B1220.1, Novus biologicals, Littleton, CO, USA), anti-DNMT3A
(1:1000, 64B1446, Novus biologicals, Littleton, CO, USA), anti-DNMT3B (1:500, orb229237, Biorbyt,
Cambridge, UK), and anti-CYCLIND (1:1000; 92G2, Cell Signaling, Massachusetts, MA, USA).
The secondary antibodies used were: mouse IgGκ light chain binding protein HRP conjugated 1:5000
(Santa Cruz sc-516102), anti-rabbit-HRP 1:5000 (Santa Cruz sc-2357), and anti-rat-HRP 1:4000 (Santa
Cruz sc-2006, Dallas, TX, USA). The blots were developed using the Luminata Crescendo Western
HRP Substrate (WBLUR0500 Millipore, Burlington, MA, USA). Western blot images were taken in a
Syngene G: BOX CHEMI XR5system (Syngene, Cambridge, UK). The membranes were stripped using
Red Blot (M2504, Inmmobilon® EMD Millipore, Burlington, MA, USA). Samples were quantified by
Fiji-ImageJ [51] after background subtraction.
2.9. DNA Extraction
Cell lysates were made using DNA lysis Buffer (100 mM Tris-HCl, 50 mM EDTA, 200 mM NaCl
and 0.2% SDS) and Proteinase K (AM2546, Thermo Fisher Scientific Waltham, MA, USA) which was
used at 100 mg/mL and samples were incubated overnight under gentle shaking. The samples were
treated with 5 µL RNAse at 10 mg/mL (800-325-3010, Roche, Basilea, Switzerland), during 1 h at 37 ◦C.
DNA extraction was performed using a classical phenol-chloroform methodology with phenol (P1037,
Sigma) and chloroform reagents (288306, Sigma). After the extraction, the DNA concentration and
purity were checked by measuring the 260/280 absorbance ratio in the Nanodrop Synergy HT (Biotek,
Winooski, VT, USA).
2.10. Quantification of DNA Methylation by Mass Spectroscopy (MS)
The extracted DNA was enzymatically hydrolyzed and the aliquoted samples (10 µL typically
containing 50 ng of digested DNA) were run in a reverse phase UPLC column (Eclipse C18 2.1 × 50 mm,
1.8 µm particle size, Agilent, Santa Clara, CA, USA) equilibrated and eluted (100 µL/min) with
water/methanol/formic acid (95/5/0.1, all by volume). The effluent from the column was added to an
electrospray ion source (Agilent Jet Stream) connected to a triple quadrupole mass spectrometer (Agilent
6460 QQQ, Santa Clara, CA, USA). The machine was operated in the positive ion multiple reaction
monitoring mode using previously optimized conditions, and the intensity of specific MH+→fragment
ion transitions were measured and recorded (5 mC m/z 242.1→126.1, 5hC 258.1→142.1 and dC m/z
228.1→112.1). The measured percentage of 5 mC in each experimental sample was calculated from the
MRM peak area divided by the combined peak areas for 5 mC plus 5hmC plus C (total cytosine pool).
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2.11. Cell Cycle Phase Determination
Cells were trypsinized and diluted in suspension in 100% ethanol. Determination of cell cycle
phase was assessed by flow cytometry using 0.5 mg/mL Propidium Iodide (P4170, Sigma, San Luis,
MO, USA) and 10 µg/mL Ribonuclease RNAse (R4642, Sigma, San Luis, MO, USA). Samples were read
using CytoFLEX Flow Cytometer (Beckman Coulter, Brea, CA, USA) and analyzed with Kaluza G for
Gallios Acquisition Software (Beckman Coulter, Brea, CA, USA).
2.12. Statistical Analyses
Statistical analyses were performed with Excel, IBM SPSS Statistics v.9 (SPSS, Chicago, IL, USA)
and Graph Pad v.6 software (Graph Pad Inc., San Diego, CA, USA). We used non-parametric statistical
tests to compare the different control and treatment conditions. Comparisons between only two groups
were made using U-Mann Whitney test. Comparisons between multiple groups were made using
Kruskal–Wallis followed by Dunn´s post hoc test. p ≤ 0.05 was considered statistically significant.
3. Results
3.1. Wnt Activity Reverses Osteogenic Cell Differentiation and Increases the Expression of Core Pluripotency
Factors in DPSCs
DPSCs were cultured in DMSO (control), DAPT, MBIO (control), BIO, and WNT-3A treatment
conditions for 48 h. When grown in standard medium containing 10% FBS, DPSCs tend to spontaneously
differentiate to mineralizing osteo/odontoblastic cell phenotypes [52,53]. Osteoblastic cell commitment
was assessed by the detection of Alkaline Phosphatase (ALP) reaction in DPSC cultures. Interestingly,
we found that the application of either BIO or WNT-3A significantly reduced ALP staining (Figure 1A,B),
suggesting that Wnt activation could revert the default osteoblastic lineage pre-differentiation
phenotype of DPSCs in standard culture conditions.
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Figure 1. Notch and Wnt signaling regulate cell differentiation and pluripotency core factor expression
in DPSCs (A): ALP activity assay showed that Wnt activation suppressed the default osteoblastic
pre-commitment in DPSCs. Scale bar = 100 µm. (B): Quantification of ALP absorbance in DPSC cultures
after WNT-3A/BIO application (C): DPSC differentiation to adipocyt s and steocytes. Pha e-Contrast
(PC) Microscopy and Alizarin S Red and Oil Red stain ng show phenotypic cha e and terminal
differentiation of control DPSCs after adipoinduction and osteoinduction treatments. Top panel:
terminal adipocyte differentiation was assessed by Oil Red (bright red spots) staining after 4 weeks,
cell nuclei are counterstained with Hematoxylin; bottom panel: terminal osteoblastic differentiation
was assessed by Alizarin Red staining after 3 weeks. Scale bar = 100 µm (Alizarin, Oil Red). Scale
bar = 20 µm (PC) (D): Q-PCR transcript expression analysis for core pluripotency factors C-MYC,
SOX2, OCT4A and NANOG between control and terminally ifferentiated DPSC cultures, and also
between control and DAPT-treated DPSCs (E): Q-PCR analysis of core factors in DPSC cultures after
BIO/WNT-3A application, with respect to their respective controls MBIO/PBS (dashed line). Data are
normalized to reference β-ACTIN and GAPDH levels and presented as the mean+SEM (n = 3). *: p < 0.05;
**: p < 0.01; ***: p < 0.001. Dunn’s Test, Kruskal- Wallis H Test. Asterisks (*) report significance with
respect to controls PBS/DMSO, and Hash symbol (#) represents significance with respect to control
MBIO. #: p < 0.05; ##: p < 0.01; ###: p < 0.001.
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We also included other treatments to induce the terminal differentiation of DPSCs to mature
cell lineages. In particular, control DPSCs were exposed to two well-established osteogenic and
adipogenic differentiation induction media [5,54]. After an induction period of between three and four
weeks, we assessed the terminal differentiation of DPSCs to osteoblasts and adipocytes, respectively.
Osteoblastic differentiation was demonstrated by the detection of mineralized bone matrix deposits
stained with Alizarin S Red after three weeks of induction (Figure 1C; bottom panel), together with an
increased expression of mature osteoblastic gene markers SPARC (Osteonectin) and OSTERIX/SP7
(Supplementary Figure S1B). Terminal differentiation of DPSCs to adipocytes was assessed by the
detection of abundant cytoplasmic lipid droplets stained with Oil Red (Figure 1C; top panel), together
with an overexpression of adipocyte gene markers PPARγ and LPL (Supplementary Figure S1A).
Adipocyte differentiation also came along with a notorious change in cellular morphology at four
weeks of induction, where DPSCs lost their usual spindle-like shape and instead adopted a rounded
cell appearance (Figure 1C; top panel).
Quantitative real time PCR analysis showed that terminally differentiated DPSCs underwent a
consistent and significant decrease in transcript expression for the pluripotency core factors c-MYC,
SOX2, OCT4 and NANOG, almost in all cases to less than half of basal control levels (Figure 1D).
A similar effect was found when DPSCs were exposed to Notch inhibitors (DAPT) for 48 h. On the
contrary, when DPSCs were exposed to Wnt activators WNT-3A or BIO for 48 h, they showed a
consistent overexpression of all core factor genes. The ones most upregulated were SOX2 and OCT4A
(Figure 1E). The upregulation of core factor expression went in parallel to a downregulation of
osteoblastic and adipogenic differentiation markers in DPSCs (Supplementary Figure S1C). OSTERIX
expression was downregulated to about half of control levels by either BIO or WNT-3A application,
thus confirming a suppression of the default osteoblastic differentiation pathway in Wnt-activated
DPSC cultures.
3.2. Notch and Wnt/β-Catenin Signaling Regulates the Cell Cycle in DPSCs
Notch and Wnt signaling were known to affect the proliferative ability of DPSCs [13]. To precisely
evaluate the impact of these treatments over the cell cycle, the relative rates of G0/G1, S and G2/M cell
cycle phases by flow cytometry were studied after exposure of DPSCs to DAPT, BIO and WNT-3A.
We observed significant differences in the cases of BIO and WNT-3A treatments with respect to controls,
with a higher proportion of cells in S-G2/M phases (20.3%, 23.75%) and a lower proportion of cells
in G0/G1 (Figure 2D,F,H). Additionally, we studied the expression of CYCLIN D1, a key regulator of
the transition between G1-S and S-G2 phases of the cell cycle. CYCLIN D1 transcription decreased
significantly in DAPT-treated DPSCs and was almost abolished in DPSCs subjected to osteogenic and
adipogenic differentiation, to less than 10% of control levels (Figure 2I). Regarding Wnt activation
treatments, BIO and WNT-3A increased CYCLIN D1 transcription in DPSCs (Figure 2J) but these
changes did not translate into changes at protein level, as assessed by WB (Figure 2G).
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Figure 2. Notch/Wnt treatment effect over cell cycle in DPSCs. (A–F): Flow cytometry analysis of
DPSC cultures exposed to different conditions for 48 h (DMSO, DAPT, MBIO, BIO, WNT-3A). Control
(E) represents DPSCs grown in standard medium. (G): Western Blot showing CYCLIN D1 protein
expression in the different conditions. (H): Representation of the percentage of cells in the different
cell cycle phases (G0/G1, S, G2/M) under each condition. Data are presented as the mean+SEM
(n = 8). (I) Q-PCR analysis of CYCLIN D1 transcript expression in DPSCs exposed to DAPT or
terminal adipogenic and osteogenic cell differentiation treatments, with respect to controls (dashed
line). (J) Q-PCR analysis of CYCLIN D1 transcript expression in BIO and WNT-3A-treated DPSCs
with respect to their respective controls MBIO/PBS (dashed line). Data are normalized to reference
β-ACTIN and GAPDH levels and presented as the mean + SEM (n = 3). *: p < 0.05; **: p < 0.01;
***: p < 0.001. Dunn’s Test, Kruskal- Wallis H Test. Asterisks (*) report significance with respect to
controls PBS/DMSO, and Hash symbol (#) represents significance with respect to control MBIO.
3.3. WNT-3A Leads to a DNA Hypo-Methylation State in DPSCs
To investigate whether Notch and Wnt signaling would also control the epigenetic profile of
DPSCs, the global DNA methylation pattern of DPSC cultures was studied by high resolution mass
spectroscopy (MS). We observed a significantly higher proportion (%) of 5methyl-cytosine (5 mC)
with respect to total cytosine in the genomic DNA of DPSCs both after the osteoinduction treatment
(2.71 ± 0.14%: p < 0.01) and adipoinduction treatment (2.81 ± 0.06%: p < 0.01) with respect to control
DPSCs (2.41 ± 0.05%; Figure 3A). Interestingly, DPSCs treated with WNT-3A significantly diminished
their % of 5 mC content (2.20 ± 0.05%: p < 0.05) whereas we did not find significant changes in BIO
(2.66 ± 0.06%) with respect to either control DMSO or MBIO (Figure 3B). Mouse ESCs (mESCs) in a
state of naïve pluripotency were included here to calibrate the system as a control of cells with very
low levels of DNA methylation [55–58]. In a previous characterization, we corroborated that these cells
presented comparatively higher levels of core factor expression than control DPSCs (Supplementary
Figure S1D–E). As expected, we found that mESCs also presented significantly lower DNA methylation
levels, as assessed by MS (1.34 ± 0.02%; Figure 3B).
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Figure 3. Notch and Wnt signaling regulate genomic DNA methylation in DPSCs. (A,B): Global DNA
methylation levels in DPSCs showing the proportion (%) of 5 mC with respect to total C in control
(DMSO, MBIO) with respect to DAPT, BIO, WNT-3A and differentiation induction conditions. Mouse
ESCs were used as a control for low DNA methylation. Data are presented as the mean+SEM (n = 8).
##: p < 0.01, ***: p < 0.001; Dunn’s post-hoc test, Kruskal- Wallis H Test. (C): Representative WB showing
DNMT1, DNMT3A and DNMT3A expression in DPSCs under different treatments. α-TUBULIN was
used as a protein loading control. Mouse ESCs were used as a positive control for DNMT protein
expression (right panel). Control on right panel shows untreated DPSCs grown in standard conditions.
In view of these results, we wondered if the decreased DNA methylation levels observed in
WNT-3A treated DPSCs could somehow be the consequence of alterations in the expression DNA
methyltransferases. The expression of the different DNA cytosine-5-methyltr nsferases (DNMT) was
assessed by WB. We found that the aintenance methyltransferase DNMT1 was the only one that could
be reliably detected at protein level in DPSCs (Figure 3C). De novo methyltransferases DNMT3A and
DNMT3B were not detected in DPSCs by WB, although they could be detected in the positive control
of mESCs, especially in the case of DNMT3A (Figure 3C; right panel). However, the qPCR analysis
determined that control DPSCs presented very small but nevertheless detectable transcript levels
for all three DNA cytosine-5-methyltransferases 1, 3A, and 3B (DNMT1, DNMT3A and DNMT3B).
The transcript expressio levels were in all cases much higher for DNMT1 than for DNMT3A and
DNMT3B, which were both marginally expressed (data not shown). Interestingly, the expression
of DNMT1, DNMT3A and DNMT3B increased hen DPSCs were exposed to osteoinduction and
adipoinduction treatments, and to the Notch inhibitor DAPT (Figure 4A). On the contrary, when we
exposed DPSC cultures to BIO or WNT-3A for 48 h, DNMT3A and DNMT3B transcript levels increased,
but DNMT1 levels were not significantly affected (Figure 4B).
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Figure 4. Notch and Wnt signaling affect the expression of methyltransferases in DPSCs. (A,B): Q-PCR
showing relative differences in DNA-methyltransferases DNMT1, DNMT3A and DNMT3B expression
in DPSCs between control (DMSO, MBIO) and DAPT, BIO, WNT-3A, adipoinduction and osteoinduction
conditions. Data are normalized to reference β-ACTIN and GAPDH levels and represented as the
mean + SEM (n = 3). (C,D): Q-PCR analysis showing relative differences in transcript expression
for the Nicotinamide-N-methyltransferase NMMT in DPSCs subjected to different treatments. Data
are normalized to reference β-ACTIN and GAPDH levels and represented as the mean+SEM (n = 3)
*: p < 0.05; **: p < 0.01; ***: p < 0.001. Dunn’s Test, Kruskal- Wallis H Test. Asterisks (*) report significance
with respect to controls PBS/DMSO, and Hash symbol (#) represents significance with respect to control
MBIO. #: p < 0.05; ##: p < 0.01.
DNA methylation reactions depend on the availability of S-adenosylmethionine (SAM)
substrate [59]. Cellular SAM is metabolized by the aforementioned DNMT enzymes, but also by
other competing ones. One of the most representative SAM-consuming enzymes is the Nicotinamide
N-methyltransferase or NNMT, which has been implicated in the generation of cellular methylation
sinks [60]. We found that NNMT was particularly highly expressed at transcript level by DPSCs (25.8%,
with respect to the housekeeping genes β-ACTIN/GAPDH: p < 0.05). Interestingly, we also found that
NNMT expression was clearly downregulated in DAPT-treated and in differentiation-induced DPSCs,
to less than half of basal control levels (Figure 4C), whereas it was upregulated in BIO and WNT-3A
treated DPSCs (11.85 ± 3.23: p < 0.05; 2.34 ± 0.36: p < 0.05, respectively; Figure 4D).
3.4. Wnt Activation Increases Histone Acetylation in DPSCs
Another important epigenetic tag which determines stemness and cell differentiation is histone
acetylation. Total protein expression levels of acetylated-Histone 3 (H3AC) were assessed by WB,
and were found to be significantly higher in WNT-3A and BIO-treated DPSCs (126 ± 11.9%: p < 0.05;
146 ± 16.5%: p < 0.05, respectively) compared to normalized controls DMSO and MBIO (Figure 5A).
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The positive control of mESCs also showed higher levels of histone acetylation compared to control
non-treated DPSCs (Figure 5A; right panel). The transcript expression levels for some known
histone acetyltransferases (HATs) and histone deacetylases (HDACs) were also assessed by qPCR.
DAPT-treated DPSCs and DPSCs which had been induced to differentiate to osteo/adipocytes had
lower gene expression levels for the acetyl-transferase HAT/KAT8, and higher expression levels for the
deacetylase HDAC/SIRT1, compared to control DPSCs (Figure 5B). On the contrary, when DPSCs were
exposed to WNT-3A and BIO, the transcript expression of HAT/KAT8 increased significantly, whereas
HDAC/SIRT1 expression was not affected (Figure 5C).
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Figure 5. Notch and Wnt signaling affect histone acetylation in DPSCs. (A): Representative WB
showing H3AC levels in control and tre ted DPSCs. α-TUBULIN was used as a protein loading control.
M use ESCs were used as a positive control for high levels of H3 acetylation (right panel). Control on
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and HDAC/SIRT1 expression i DAPT-treated and osteo/adipoinduced DPSC cultures. (C): Q-PCR
analysis of WNT-3A/BIO treated DPSC cultures for HAT/KAT8 and HDAC/SIRT1. Data are normaliz d
to reference β-ACTIN and GAPDH levels and presen ed as the mean + SEM (n = 3). *: p < 0.05;
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3.5. Wnt Activation Modifies the Histone H3 Methylation Pattern in DPSCs
In order to assess whether the pattern of H3 methylation was also affected by exposure of DPSCs to
Notch and Wnt regulators, a WB analysis was performed against tri-methylated H3 Histones H3K4me3,
H3K27me3 and H3K9me3. We found that protein expression levels were significantly increased for
most of these three methylation tags in BIO, and especially, in WNT-3A treated DPSCs (H3K4me3:
133 ± 21,56%, p < 0.01; H3K27me3: 337 ± 67,22%, p < 0.05; and H3K9me3: 362 ± 27,5%, p < 0.05
respectively; Figure 6A), compared to their respective normalized controls. These results showed that
Wnt activation changed the epigenetic footprint of DPSCs also at histone methylation level. Pluripotent
mESCs also showed higher overall levels for all the three H3 methylation tags H3K4me3, H3K27me3,
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and H3K9me3, compared to control DPSCs (Figure 6A; right panel). Finally, we analyzed by qPCR
the relative transcript expression for the key catalytic subunits responsible for each of these three H3
trimethylations: MLL (H3K4me3), EZH2 (H3K27me3), and EHMT2 (H3K9me3). We found that BIO
and WNT-3A induced significant increases in the expression for MLL, EZH2, and EHMT2 in DPSCs.
In contrast, terminal differentiation of DPSCs to osteocytes and adipocytes induced a downregulation
of MLL, EZH2, and EHMT2 at the transcript level (Figure 6B,C).
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protein levels of trimethylated H3K4me3, H3K27me3, and H3K9me3. α-TUBULIN was used as a
protein loading control. Mouse ESCs were used as a positive control for high H3 methylation (right
panel). Control on right panel shows untreated DPSCs grown in standard conditions. (B,C): Q-PCR
analyses showing transcript expression levels for histone-methyltransferases placing H3K4me3 (MLL),
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Dunn’s Test, Kruskal- Wallis H Test. Asterisks (*) report significance with respect to controls PBS/DMSO,
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4. Discussion
Traditional reprogramming methods of somatic cells rely on permanent genetic modification,
which compromises the safety of these therapies for clinical use [61–63]. Hence, there is an amply
justified in erest in finding sources of uman cells with a suitable epig netic profile for a less inv sive
reprogramming. In this regard, DPSCs have emerged as some of the most promising candidates to
cover the exist nt gap between research and the clinic. DPSCs show an exceptional ability for full c ll
reprogramming to iPSCs, even without a need for genome-inte rating vectors [25].
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Several studies have described canonical Notch and Wnt signaling pathways as pivotal regulators
of stemness and pluripotency [40,64–72], and their pharmacological manipulation has already
been tested as a strategy to enhance either cell differentiation [73] or cell reprogramming [13,74].
The pluripotency network comprises a core set transcription factors, including OCT4A (POUF51F),
SOX2 and NANOG, which serve to establish the undifferentiated state and the self-renewal capacity
of pluripotent stem cells [27]. This network interacts with the cell cycle machinery. The cell cycle of
PSCs is characterized by a rapid progression and a minimal time spent in G1 [75–77]. In DPSCs treated
with the Wnt activators BIO and WNT-3A, we did not find more than a 7% change in cells on G1/G0
phases of the cell cycle, compared to controls DMSO and MBIO. These changes were corroborated
by numerous experiments and support the findings of previous studies [13] suggesting that these
pharmacological treatments induced only a mild effect on DPSC proliferation and self-renewal.
DNA methylation is a critical regulator of stem cell differentiation. Interestingly, it has been
described that the DNA methyltransferase inhibitor 5-aza-2′-deoxycytidine (5-aza-dC) is able to increase
the stemness of periodontal ligament stem cells (PDLSCs), and also to enhance the reprogramming
efficiency of human gingival mesenchymal stem cells (hGMSCs) [26,78]. Another report showed that
a short pre-application of 5-aza-dC for 24 h increased the responsiveness of DPSCs to osteogenic
differentiation protocols [79], a similar result to the one obtained after preconditioning DPSCs for 48 h
with BIO or WNT-3A, as we showed in our own previous research [13]. Regarding other epigenetic
marks such as acetylation, it was reported that p300, a well-known histone acetyltransferase, also
played an important role in maintaining the stemness of DPSCs [80]. Moreover, different types of
histone deacetylases or HDACs such as HDAC1, HDAC2, HDAC3, HDAC4, and HDAC9 act as
important accelerators of odontoblast differentiation [81–83] and a similar effect has been described
for histone demethylases like KDM6B, which removes H3K27me3 tags [84]. All of these evidences
indicate an important regulatory circuit involving DNA and histone modifications that are crucial in
determining the cell fate in DPSCs, and at least in some cases, these epigenetic regulations are linked
to the Notch and Wnt signaling pathways, whose activities are mutually interdependent in these
cells [13].
In our research model we induced DPSC cultures to generate terminally differentiated cells of
osteocyte and adipocyte lineages. Pharmacological induction of DPSC differentiation increased DNA
methylation with respect to control DPSC levels, corroborating the widely held view that somatic
differentiated cells present a more methylated genome than stem cells [85]. Nevertheless, the most
interesting findings of this work refer to the changes induced by Wnt/β-catenin signaling activation
on the epigenetic profile of DPSCs. The recombinant protein WNT-3A, applied for just 48 h, induced
a significant genomic DNA demethylation and a significant increase of global H3 acetylation in
primary DPSC cultures. A genomic DNA methylation assessment by MS enabled us to establish a
cell differentiation scale according to the levels of 5 mC, where terminally differentiated DPSCs to
osteocytes and adipocytes had the highest levels of methylation, whereas naïve pluripotent PSCs
showed the lowest. Based on these results, we think that MS could be a useful tool to monitor the
global cell determination state of DPSCs and other stem cell cultures.
The principal DNA methyltransferase expressed by DPSCs was DNMT1. This maintenance
methyltransferase only acts on hemimethylated DNA strands and is essential for the transmission of
DNA methylation patterns to the daughter cells after DNA replication [86,87] In our model, we did
not find significant changes in DNMT1 transcript and/or protein levels in DPSCs after Wnt activation.
Regarding de novo methyltransferases DNMT3A and DNMT3B, their expression in DPSCs was very
small and only found at the transcript level. Thus, it is unlikely that solely an altered expression of DNA
methyltransferases could on its own account for the changes in genome methylation observed in DPSCs
after WNT-3A exposure. It is more plausible that changes in DNA methyltransferase activity and/or
DNA methylation turnover could be responsible for this effect [88] For instance, DNA methylation
reactions require very large pools of available S-adenosylmethionine (SAM) as a substrate for the
DNA methyltransferases, and thus these enzymes must compete with other SAM-consuming cellular
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methyltransferases like Nicotinamide-N-methyltransferase (NNMT), whose increased expression
has been reported to generate methylation sinks [89]. Interestingly, the basal NNMT transcript
expression levels in DPSCs were found to be characteristically high, and this expression was increased
by several-fold under Wnt activation, thus providing a potential mechanism to explain the global
decrease in DNA methylation levels observed in treated DPSCs. Other alternative mechanisms rely on
the interplay between DNA methylation and histone acetylation [90].
In this study, increased levels of histone acetylation in DPSCs were found after exposure to
WNT-3A. This has a direct connection with a recently described metabolic reprogramming induced by
Wnt activation in these cells. Our previous research demonstrated that the treatment with WNT-3A
exactly in the same conditions as in the present study activated both mitochondrial metabolism
and lipid synthesis in DPSCs [91]. De novo cytoplasmic production of fatty acids requires a high
availability of acetyl-coA, which comes primarily from citrate leaving the mitochondria in a process
called cataplerosis [92]. Once in the cytosol this citrate is metabolized by the ATP-citrate lyase
(ACLY) enzyme, also overexpressed in Wnt-activated DPSCs [91], which generates cytoplasmic and
nuclear pools of acetyl-coA. The increased lipid synthesis observed in Wnt-activated DPSCs strongly
suggests the possibility of cyto/nucleoplasmic acetyl-coA accumulation [91]. Importantly, high levels
of acetyl-coA not only sustain lipid synthesis, but also histone acetylation, and this is known to be
crucial for the maintenance of stemness and pluripotency [36,93]. Moreover, these stored lipids could
also eventually become a reliable ready-to-use fuel for new acetyl-coA generation, thus sustaining high
histone acetylation levels in the cell nucleus [91]. Thus, compelling evidence points to the coordinated
activation of mitochondrial and lipid metabolism as a mechanism promoting an increased histone
acetylation under Wnt activation in DPSCs. Finally, acetylation-induced transcription could also
indirectly account for a global genomic DNA demethylation effect, as the latter has been proposed as a
memory mechanism for active gene transcription [94].
Stem cells and particularly PSCs are also known to present different histone methylation patterns
compared to somatic differentiated cells, where the most studied are trimethylation marks in H3 [38].
Interestingly, after WNT-3A exposure we found that the levels for both activating (H3K4me3) and
repressing (H3K9me3, H3K27me3) H3 trimethylation tags were increased in DPSCs. These studies are
in concordance with observations in ESCs where activating marks such as H3K4me3 are known to be
combined with H3K27me3 repressive marks in lineage-specific genes [95]. Thus, it is tempting to argue
that exposure to WNT-3A induces a chromatin remodeling in DPSCs, to approach PSC characteristics.
More studies would be necessary to analyze whether these changes in H3 trimethylation are directly
related to the emergence of bivalent gene promoters in DPSCs after Wnt activation.
5. Conclusions
In this article, we hypothesized that the metabolic remodeling induced in DPSCs by Wnt activation
could also have an impact in the epigenetics of DPSCs. We found out that WNT-3A exposure induced
multifaceted epigenetic reprogramming in DPSCs, characterized by a global DNA hypomethylation, a
global histone hyperacetylation, and an increase in both activating and repressing histone methylation
marks, which constitute the most typical epigenetic footprints of PSCs. These findings shed light
on how stemness, signaling, metabolic, and epigenetic networks cooperate in DPSCs, and they
could also have important implications to optimize the clinical use of these cells. The fact that a
simple pharmacological treatment with WNT-3A can induce a chromatin remodeling in DPSCs brings
important practical advantages with a view to cell therapy, such as the possibility to keep these cells
for longer periods in culture in the presence of FBS, without compromising their stemness properties
due to spontaneous in vitro osteoblastic differentiation. Another potential application could be to
design better and more efficient protocols for the differentiation of DPSCs to many different lineages of
somatic cells. Finally, this work could also contribute to the development of gentler, safer, and more
efficient full cell reprogramming strategies using DPSCs.
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